• Home
  • About
  • Policies
  • Contact
    • English
    • Türkçe
  • English 
    • English
    • Türkçe
  • Login
Advanced Search
View Item 
  •   Home
  • Tüm Akademik Yayınlar
  • Yeni Yayınlar
  • View Item
  •   Home
  • Tüm Akademik Yayınlar
  • Yeni Yayınlar
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma.

Thumbnail
View/Open
The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma.pdf (812.7Kb)
Date
2022-05-14
Author
Topcu, Atakan
Ozturk, Akin
Yurtsever, İSMAİL
Besiroglu, Mehmet
Yasin, Ayse Irem
Turk, Haci Mehmet
Seker, Mesut
Advisor
Type
Article
Metadata
Show full item record
Abstract
Erlotinib, a tyrosine kinase inhibitor, has been shown to improve the survival of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Sarcopenia is a status with increasing importance in lung cancer, and it may predict a poor prognosis. We aimed to evaluate the impact of sarcopenia on erlotinib therapy and prognosis in patients with EGFR-mutated (exon 19 or 21 L858R) metastatic lung adenocarcinoma. Sarcopenia was defined as skeletal muscle index ≤39 cm2/m2 for women and ≤55 cm2/m2 for men. The patient characteristics, inflammation parameters, clinical and survival outcomes of the erlotinib therapy were examined according to sarcopenia status. We also analyzed the erlotinib treatment-related toxicity. Seventy-two patients were included in our retrospective study, and the mean age of the patients was 63.7 years. A total of 39 (54.2%) patients were diagnosed with sarcopenia. Patients with sarcopenia had a poor prognosis and had a shorter median progression-free survival (PFS) than patients without sarcopenia (10.5 months vs. 21.8 months, p=0.002). Sarcopenia (HR 2.08) and C-reactive protein > 6.5 mg/L (HR 2.57) were determined as independent poor prognostic factors for PFS of erlotinib therapy. Treatment-related toxicity occurred in 34.7% of patients treated with erlotinib, and sarcopenia did not significantly affect treatment-related toxicity. We also found that sarcopenia significantly affected the response to erlotinib. The expected survival outcomes may be low when erlotinib therapy is used in patients with sarcopenia and metastatic lung adenocarcinoma. This study showed that survival and clinical outcomes could be better predicted by detecting sarcopenia in patients with lung cancer using erlotinib.
Subject
Lung cancer
Sarcopenia
Erlotinib
Adenocarcinoma
Prognosis
URI
http://hdl.handle.net/20.500.12645/30645
Collections
  • Yeni Yayınlar

BEZMIALEM VAKIF UNIVERSITY

About us |Policies | Library | Contact us | Send Feedback | Sitemap | Admin

Bezmialem Vakıf Üniversitesi, Adnan Menderes Bulvarı Vatan Caddesi 34093 Fatih, İstanbul / TURKEY
Copyright © Bezmialem Vakıf Üniversitesi

Creative Commons Lisansı
Bezmialem Institutional Repository, Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

OpenAccess@BVU

Support by  UNIREPOS






sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypeLanguageRightsAdvisorInstitution AuthorThis CollectionBy Issue DateAuthorsTitlesSubjectsTypeLanguageRightsAdvisorInstitution Author

My Account

LoginRegister

BEZMIALEM VAKIF UNIVERSITY

About us |Policies | Library | Contact us | Send Feedback | Sitemap | Admin

Bezmialem Vakıf Üniversitesi, Adnan Menderes Bulvarı Vatan Caddesi 34093 Fatih, İstanbul / TURKEY
Copyright © Bezmialem Vakıf Üniversitesi

Creative Commons Lisansı
Bezmialem Institutional Repository, Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

OpenAccess@BVU

Support by  UNIREPOS